| |
Newsroom /
Health and Fitness
/
Healthcare
/
USciences and TTC to Sponsor Pharmaceutical Leaders at a Key Conference in Philadelphia
USciences and TTC to Sponsor Pharmaceutical Leaders at a Key Conference in Philadelphia
"Representatives from Top Pharmaceuticals and CRO Firm will be in attendance"
Philadelphia,
PA,
United States of America
(prbd.net)
08/11/2011
TTC, llc and the University of the Sciences in Philadelphia (USciences) announce highly renowned leaders in the Pharmaceutical and CRO industries to speak at the “The 2nd Annual State of Clinical Development Cost" conference. This 2-day event will feature key speakers such as John Hubbard, Ph.D., F.C.P., Senior Vice President and Worldwide Head, Development Operations at Pfizer and Peter Aurup, MD., Vice President, Head Global Clinical Trial Operations at Merck. Dr. Hubbard will bring to light the current industry practices in the pharmaceutical industry while Dr. Aurup will be discussing the future challenges pharmaceutical companies will be facing.
There will be five panels of highly renowned professionals that include industry leaders such as Peter Carberry, Sr. VP Global Development Operations at Astellas, Mitchell Katz, Ph.D., Executive Director, Medical Research Operations, at Purdue, Kate Tranotti, VP of Clinical Operations at ICON, and Alan Braverman, Vice President of North American Operations at PSI. All four panelists have been in the industry 25+ years and are experts in their fields.
TTC “2nd Annual State of Clinical Development Cost” conference panels will address topics such as ‘The Value of Cost Data to Upper Management’, ‘Working with Countries that are Difficult to Budget and Negotiate’, Standard of Care Trends and Case Studies’, Late Phase Study Planning and Budgeting’, and a second day panel on ‘CRO’s’
USciences has also announced that all proceeds from the conference will be devoted to pursue evidence based research issues that arise from those who attended the conference.
Harold Glass, TTC Principal, and USciences Professor, summed up the upcoming conference as, “The “2nd Annual State of Clinical Development Cost” will focus on managing clinical development costs based on current industry trends, improving ROI, and increasing compliance. We are bringing together some of the best thinkers in the industry and academia for two days of notable keynote addresses, one-on-one talks, and panel discussions that covered the most up-to-date empirical research and experiences of leading edge companies.”
To find more information on the conference, please visit http://www.stateofclindev.com
About
TC is the leader in global clinical trial cost benchmarking. In fact, we invented it. In 1990, TTC principle, Dr. Harold E. Glass founded the first drug development cost benchmarking company in the world. Today, 10 year old TTC, with offices in Philadelphia, Pennsylvania and London, England has a proven track record in all aspects of outsourcing cost management; from the budgeting of protocols and clinical trials to the negotiations with clinical sites and other providers.
|